<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648089</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2007-03</org_study_id>
    <nct_id>NCT00648089</nct_id>
  </id_info>
  <brief_title>EPOMI Study: ErythroPOietin in Myocardial Infarction</brief_title>
  <acronym>EPOMI</acronym>
  <official_title>ErythroPOietin in Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the
      effects of a single erythropoietin administration on infarct size and cardiac remodeling in
      patients with acute myocardial infarction. Eligible patients will be randomly assigned to
      receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional
      therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac
      magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months
      later.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in infarct size as assessed by magnetic resonance imaging 3 months after administration of study medication</measure>
    <time_frame>within 3-7 days of administration of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-systolic volume, end-diastolic volume, ejection fraction</measure>
    <time_frame>within 3-7 days of administration of study medication, and 3 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobin, platelets, reticulocytes blood count</measure>
    <time_frame>during the first 10 days following study medication administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major cardiac event or venous thrombotic events</measure>
    <time_frame>within 12 months following administration of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO</intervention_name>
    <description>Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-Segment elevation myocardial infarction &lt;6h

          -  Infarct related artery : proximal circumflex artery , proximal and mid left anterior
             descending artery, 1st segment of the right coronary artery

          -  TIMI 0 or 1 before angioplasty

          -  Successful PCI defined by residual stenosis &lt; 50% and TIMI 2 or 3 flow grade

          -  Body weight : [50-110] kg

          -  Informed, written consent

        Exclusion Criteria:

          -  Age &lt; 18

          -  Pregnant, or parturient or breast-feeding women;

          -  Sexually active women without efficient contraception;

          -  Inability to fully cooperate with the study protocol

          -  Pre-treatment with fibrinolysis ;

          -  Previous Q-wave myocardial infarction or previous aorto-coronary bypass;

          -  History of deep vein thrombosis or pulmonary embolism;

          -  Contraindication to aspirin or clopidogrel ;

          -  Cardiogenic shock ;

          -  Cardiac resuscitated before angioplasty ;

          -  Past or active erythropoietin therapy;

          -  Contraindications to erythropoietin therapy: uncontrolled hypertension, known
             hypersensitivity to benzoic acid, chronic liver insufficiency, hemoglobin&gt; 16g / l,
             thrombocytosis, refractory anemia with excess of blasts;

          -  Renal insufficiency (creatinine clearance &lt;30ml/mn.);

          -  Active Malignancies

          -  Any contraindications to magnetic resonance imaging: pacemaker and automatic cardiac
             defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in
             the eye, ferromagnetic haemostatic clips in the central nervous system cochlear
             implants, claustrophobia;

          -  Allergy to gadolinium ;

          -  Patient refusal / patient not having provided written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice PRUNIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fabrice PRUNIER, MD, PhD,</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>January 28, 2011</last_update_submitted>
  <last_update_submitted_qc>January 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fabrice PRUNIER, MD, PhD</name_title>
    <organization>University Hospital, Angers</organization>
  </responsible_party>
  <keyword>Acute ST Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

